There is now a key opportunity to prevent the avoidable loss of life from infection, reduce the proliferation of antimicrobial resistant bacteria, and minimise the excess healthcare cost of sub-optimal treatment.

CRE RESPOND will unite an expert and targeted network, with a:

  • Shared vision to enhance clinician decision-making to reduce the burden that sub-optimal dosing has on patients, the healthcare system and the community.
  • Strategy for a comprehensive program of research designed to translate new knowledge into evidence-based personalised antimicrobial dosing and ensure our research continues to impact health policy and practice change leading to better patient outcomes.
  • Structure for clear internal and external governance, and in partnership with clinicians as end-users and with patients, their families and engaged members of the community as consumers.
  • System established within The University of Queensland, one of Australia‚Äôs most comprehensive research-intensive universities equipped with the infrastructure to support this international CRE.
  • Staff with career development pathways to build present and future research capacity, as well as established dissemination tools to educate and develop the health and medical research workforce.
  • Significance for improved care of patients with infection through the delivery of evidence-based, personalised antimicrobial dosing, optimised to reduce the threat of antimicrobial resistance.

The CRE RESPOND projects are organised into four workstreams and led by various members of the research team.